Navigation Links
DuPont Responds to Spelter, W.Va. Lawsuit Rulings
Date:2/26/2008

Company Will Appeal to State Supreme Court

WILMINGTON, Del., Feb. 26 /PRNewswire-FirstCall/ -- The following statement is in response to the rulings in the Spelter, W.Va., zinc smelter class action lawsuit late Monday. The statement is to be attributed to DuPont General Counsel Stacey J. Mobley.

"We are extremely disappointed by the rulings in the Spelter case. DuPont will appeal this case, including the recent rulings and the earlier jury verdicts. We believe there were numerous errors, both during and after trial, that deprived the company of a fair outcome in this case. We are hopeful that the Supreme Court of Appeals of West Virginia will grant review.

"The scientific evidence simply does not warrant medical monitoring. We believe the evidence presented both at trial and in the post-trial proceedings shows that there is no increased risk of disease to the class members as a result of the smelter.

"The court's decision to include biennial chest CT scans in the medical monitoring program is particularly troubling. CT scans are not recommended for such medical monitoring because the risks of harm, including risks of cancer due to radiation exposure, outweigh any benefits. This determination is supported by a recent study published in the New England Journal of Medicine. The trial evidence showed that neither the U.S. Preventive Services Task Force, nor any other authoritative medical screening authority, recommends CT scans for screening asymptomatic patients. The court's rulings, which adopt a plan that includes regular CT scans, ignore the consensus of the medical community.

"The court also erred in estimating the cost of the medical monitoring program at $130 million. Plaintiffs' counsel presented a grossly inflated cost projection as justification for a larger award of attorneys' fees. This estimate is based on implausible and inflated assumptions and forecasts about medical costs and participation rates for the class members. This projection overestimates the reasonable expected cost of the program by many tens of millions of dollars. DuPont's funding obligations will be based on the actual cost of the program, not plaintiffs' unrealistic estimate."

DuPont (NYSE: DD) is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.


'/>"/>
SOURCE DuPont
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DuPont Pledges $1 Million to World Food Prize
2. DuPont Hosts Meeting of Leading Plant Scientists to Improve World Agricultural Productivity
3. Perdue AgriBusiness Announces Low Linolenic Soybean Contracting Opportunities with DuPont Business Pioneer Hi-Bred
4. DuPont Announces Leadership Changes
5. DuPont Opens Fluoropolymer Production Plant in China
6. DuPont Licenses Breakthrough Automotive Coating Technology to German Paint Maker
7. New DuPont(TM) Agility(TM) SG Herbicide Offers Wheat Growers Answers to Changing Weed Control Needs
8. DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber
9. DuPont Names Phuong Tram Chief Information Officer
10. DuPont Group Vice President Briefs Investors on Performance Materials Segment
11. DuPont Responds to Spelter, W.Va., Lawsuit Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: